306 related articles for article (PubMed ID: 11046034)
1. Functional defects of NK cells treated with chloroquine mimic the lytic defects observed in perforin-deficient mice.
Austin Taylor M; Bennett M; Kumar V; Schatzle JD
J Immunol; 2000 Nov; 165(9):5048-53. PubMed ID: 11046034
[TBL] [Abstract][Full Text] [Related]
2. Perforin- and Fas-dependent mechanisms of natural killer cell-mediated rejection of incompatible bone marrow cell grafts.
Taylor MA; Ward B; Schatzle JD; Bennett M
Eur J Immunol; 2002 Mar; 32(3):793-9. PubMed ID: 11870623
[TBL] [Abstract][Full Text] [Related]
3. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin.
Hayakawa Y; Kelly JM; Westwood JA; Darcy PK; Diefenbach A; Raulet D; Smyth MJ
J Immunol; 2002 Nov; 169(10):5377-81. PubMed ID: 12421908
[TBL] [Abstract][Full Text] [Related]
4. Mapping of quantitative trait loci determining NK cell-mediated resistance to MHC class I-deficient bone marrow grafts in perforin-deficient mice.
Johansson MH; Taylor MA; Jagodic M; Tus K; Schatzle JD; Wakeland EK; Bennett M
J Immunol; 2006 Dec; 177(11):7923-9. PubMed ID: 17114464
[TBL] [Abstract][Full Text] [Related]
5. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells.
Screpanti V; Wallin RP; Ljunggren HG; Grandien A
J Immunol; 2001 Aug; 167(4):2068-73. PubMed ID: 11489989
[TBL] [Abstract][Full Text] [Related]
6. NK cells rapidly reject allogeneic bone marrow in the spleen through a perforin- and Ly49D-dependent, but NKG2D-independent mechanism.
Hamby K; Trexler A; Pearson TC; Larsen CP; Rigby MR; Kean LS
Am J Transplant; 2007 Aug; 7(8):1884-96. PubMed ID: 17617852
[TBL] [Abstract][Full Text] [Related]
7. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum.
Smyth MJ; Kelly JM; Baxter AG; Körner H; Sedgwick JD
J Exp Med; 1998 Nov; 188(9):1611-9. PubMed ID: 9802973
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the death receptor pathway by cFLIP confers partial engraftment of MHC class I-deficient stem cells and reduces tumor clearance in perforin-deficient mice.
Taylor MA; Chaudhary PM; Klem J; Kumar V; Schatzle JD; Bennett M
J Immunol; 2001 Oct; 167(8):4230-7. PubMed ID: 11591744
[TBL] [Abstract][Full Text] [Related]
9. Regulation of perforin-independent NK cell-mediated cytotoxicity.
Wallin RP; Screpanti V; Michaëlsson J; Grandien A; Ljunggren HG
Eur J Immunol; 2003 Oct; 33(10):2727-35. PubMed ID: 14515256
[TBL] [Abstract][Full Text] [Related]
10. Perforin is a major contributor to NK cell control of tumor metastasis.
Smyth MJ; Thia KY; Cretney E; Kelly JM; Snook MB; Forbes CA; Scalzo AA
J Immunol; 1999 Jun; 162(11):6658-62. PubMed ID: 10352283
[TBL] [Abstract][Full Text] [Related]
11. Antigen-primed CD8+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing.
Komatsu M; Mammolenti M; Jones M; Jurecic R; Sayers TJ; Levy RB
Blood; 2003 May; 101(10):3991-9. PubMed ID: 12521999
[TBL] [Abstract][Full Text] [Related]
12. Distinct requirements for IFNs and STAT1 in NK cell function.
Lee CK; Rao DT; Gertner R; Gimeno R; Frey AB; Levy DE
J Immunol; 2000 Oct; 165(7):3571-7. PubMed ID: 11034357
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
14. Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice.
Baker MB; Podack ER; Levy RB
Biol Blood Marrow Transplant; 1995 Dec; 1(2):69-73. PubMed ID: 9118294
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells.
Yu Y; Hagihara M; Ando K; Gansuvd B; Matsuzawa H; Tsuchiya T; Ueda Y; Inoue H; Hotta T; Kato S
J Immunol; 2001 Feb; 166(3):1590-600. PubMed ID: 11160200
[TBL] [Abstract][Full Text] [Related]
16. The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent.
Mori S; Jewett A; Murakami-Mori K; Cavalcanti M; Bonavida B
Cancer Immunol Immunother; 1997 Jul; 44(5):282-90. PubMed ID: 9247563
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides.
Ortaldo JR; Young HA; Winkler-Pickett RT; Bere EW; Murphy WJ; Wiltrout RH
J Immunol; 2004 Jan; 172(2):943-53. PubMed ID: 14707067
[TBL] [Abstract][Full Text] [Related]
18. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
[TBL] [Abstract][Full Text] [Related]
19. Cutting edge: granzymes A and B are not essential for perforin-mediated tumor rejection.
Smyth MJ; Street SE; Trapani JA
J Immunol; 2003 Jul; 171(2):515-8. PubMed ID: 12847210
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic T cells specifically induce Fas on target cells, thereby facilitating exocytosis-independent induction of apoptosis.
Simon MM; Waring P; Lobigs M; Nil A; Tran T; Hla RT; Chin S; Müllbacher A
J Immunol; 2000 Oct; 165(7):3663-72. PubMed ID: 11034370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
